Eternity Biotech Launches Crowdfunding Campaign on Wefunder to Accelerate Anti-Aging Product Development
02 Apr 2024
NEW YORK, April 2, 2024 /PRNewswire/ -- Eternity Biotech, Inc. (the "Company", "Eternity"), a biotechnology company dedicated to finding solutions for longer, healthier lives, today announced the launch of a crowdfunding campaign on Wefunder to advance its anti-aging product development.
A spin out from Yale University, Eternity's revolutionary approach hinges on targeted expression of genes identified in the nematode worm that play significant roles in cell division and protection from stress. Through precision microinjection techniques focused on these genes, Yale researchers were able to increase the lifespan of nematodes by 25% and increased their ability to confront and conquer stressors such as oxidative challenges, apoptosis, and DNA damage. After replicating these results in human cells, Eternity looks to develop this technology and identify a novel candidate in the anti-aging space.
"With this campaign, we look to usher in a new era of growth and development for Eternity and within the broader anti-aging sector of life science research," said Joseph Hernandez, Chairman and Chief Executive Officer of Eternity. "The exciting part about this platform is that it allows investors of all sizes and backgrounds to get involved in biotech investing while simultaneously supporting our mission and company growth. We are thrilled to welcome our new investors and strive towards longer, healthier lives for all."
The Company is 'testing the waters' to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder's platform. Any indication of interest involves no obligation or commitment of any kind.
For media inquiries, please contact [email protected].
About Eternity Biotech, Inc.
Emanating from the distinguished research laboratories of Yale University, the very essence of Eternity Biotech is grounded in the belief that human experience can transcend its traditional boundaries. We envision a world where aging is not an inevitability, but a challenge to be met with cutting-edge technology and innovative solutions. Through dedicated research and development, we have identified genes that play a key role in cell division and protection from stressors, proved both in a nematode model and in human cells. Our mission is to further develop this technology into an effective solution to combat aging for all. To learn more about our mission and technology, visit our website at www.eternitybio.com and follow us on LinkedIn for news and updates.
SOURCE Eternity Biotech, Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.